CAPTRUST Financial Advisors
VYNE icon

CAPTRUST Financial Advisors’s VYNE Therapeutics VYNE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7
Closed – – 4776
2021
Q2 		$0 Hold
7
– – ﹤0.01% 4669
2021
Q1 		$1K Buy
+7
New +$1.01K ﹤0.01% 4250

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAPTRUST Financial Advisors's VYNE Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 7 shares.

CAPTRUST Financial Advisors first reported a position in VYNE in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2021. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 7 VYNE Therapeutics shares in Q3 2021.
  • CAPTRUST Financial Advisors first reported a position in VYNE Therapeutics in Q1 2021 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's VYNE Therapeutics position peaked at $1K in Q1 2021.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.